Key Insights on Gross Profit: AbbVie Inc. vs Amphastar Pharmaceuticals, Inc.

AbbVie vs. Amphastar: A Decade of Financial Growth

__timestampAbbVie Inc.Amphastar Pharmaceuticals, Inc.
Wednesday, January 1, 20141553400000051256000
Thursday, January 1, 20151835900000077347000
Friday, January 1, 201619805000000104189000
Sunday, January 1, 20172117600000090795000
Monday, January 1, 201825035000000106985000
Tuesday, January 1, 201925827000000131923000
Wednesday, January 1, 202030417000000143340000
Friday, January 1, 202138751000000199739000
Saturday, January 1, 202240640000000248860000
Sunday, January 1, 202333903000000351121000
Monday, January 1, 20240
Loading chart...

Unleashing the power of data

A Tale of Two Companies: AbbVie Inc. vs. Amphastar Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, the financial health of companies is a key indicator of their market position and potential for growth. Over the past decade, AbbVie Inc. has demonstrated a robust financial trajectory, with its gross profit soaring by approximately 118% from 2014 to 2023. This impressive growth underscores AbbVie's strategic prowess and market dominance.

Conversely, Amphastar Pharmaceuticals, Inc. has shown a more modest increase in gross profit, growing by around 585% over the same period. While Amphastar's growth rate is significant, its absolute figures remain a fraction of AbbVie's, highlighting the contrasting scales at which these companies operate.

This comparison not only reflects the diverse strategies and market positions of these two pharmaceutical giants but also offers insights into the broader industry trends shaping their futures.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025